Masson V - Search Results

1

[Multidisciplinary management of the pediatric sickle cell patient in 2019].

Hoyoux M, Snoeck M, Sondag C, Ketelslegers O, Minon JM, Azerad MA, Masson V, Dresse MF. Hoyoux M, et al. Among authors: masson v. Rev Med Liege. 2019 Nov;74(11):586-592. Rev Med Liege. 2019. PMID: 31729847 Free article. French.

2

[Non-observance and therapeutic inertia in obstetrics].

Masson V, Petit P, Foidart JM. Masson V, et al. Rev Med Liege. 2010 May-Jun;65(5-6):395-8. Rev Med Liege. 2010. PMID: 20684426 Free article. French.

3

[Female Genital Mutilations : the condition in Liege].

Swenen L, Brichant G, Kaluanga A, Masson V, Nisolle M. Swenen L, et al. Among authors: masson v. Rev Med Liege. 2017 Jan;72(1):25-31. Rev Med Liege. 2017. PMID: 28387074 Free article. French.

4

[Addictions and pregnancy : how to ruin a pregnancy].

Emonts P, Masson V, Chantraine F, Kridelka F, Nisolle M. Emonts P, et al. Among authors: masson v. Rev Med Liege. 2013 May-Jun;68(5-6):239-44. Rev Med Liege. 2013. PMID: 23888571 Free article. French.

5

[Role of plasminogen activator inhibitor type 1 in tumor angiogenesis].

Bajou K, Devy L, Masson V, Albert V, Frankenne F, Noël A, Foidart JM. Bajou K, et al. Among authors: masson v. Therapie. 2001 Sep-Oct;56(5):465-72. Therapie. 2001. PMID: 11806282 Review. French.

6

Contribution of host MMP-2 and MMP-9 to promote tumor vascularization and invasion of malignant keratinocytes.

Masson V, de la Ballina LR, Munaut C, Wielockx B, Jost M, Maillard C, Blacher S, Bajou K, Itoh T, Itohara S, Werb Z, Libert C, Foidart JM, Noël A. Masson V, et al. FASEB J. 2005 Feb;19(2):234-6. doi: 10.1096/fj.04-2140fje. Epub 2004 Nov 18. FASEB J. 2005. PMID: 15550552 Free PMC article.

7

Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization.

Bajou K, Noël A, Gerard RD, Masson V, Brunner N, Holst-Hansen C, Skobe M, Fusenig NE, Carmeliet P, Collen D, Foidart JM. Bajou K, et al. Among authors: masson v. Nat Med. 1998 Aug;4(8):923-8. doi: 10.1038/nm0898-923. Nat Med. 1998. PMID: 9701244 Free article.

8

Role of plasminogen activator-plasmin system in tumor angiogenesis.

Rakic JM, Maillard C, Jost M, Bajou K, Masson V, Devy L, Lambert V, Foidart JM, Noël A. Rakic JM, et al. Among authors: masson v. Cell Mol Life Sci. 2003 Mar;60(3):463-73. doi: 10.1007/s000180300039. Cell Mol Life Sci. 2003. PMID: 12737307 Free article. Review.

9

The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies.

Bajou K, Masson V, Gerard RD, Schmitt PM, Albert V, Praus M, Lund LR, Frandsen TL, Brunner N, Dano K, Fusenig NE, Weidle U, Carmeliet G, Loskutoff D, Collen D, Carmeliet P, Foidart JM, Noël A. Bajou K, et al. Among authors: masson v. J Cell Biol. 2001 Feb 19;152(4):777-84. doi: 10.1083/jcb.152.4.777. J Cell Biol. 2001. PMID: 11266468 Free PMC article.

10

The pro- or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent.

Devy L, Blacher S, Grignet-Debrus C, Bajou K, Masson V, Gerard RD, Gils A, Carmeliet G, Carmeliet P, Declerck PJ, Nöel A, Foidart JM. Devy L, et al. Among authors: masson v. FASEB J. 2002 Feb;16(2):147-54. doi: 10.1096/fj.01-0552com. FASEB J. 2002. PMID: 11818362

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

189 results

Search Page